Cell metabolism is gaining recognition as a critical element of cell function in both normal and disease-associated processes such as immune cell activation, cancer proliferation, and stem cell reprogramming, as well as mitochondrial toxicity. As such, early drug discovery efforts involve understanding how cell metabolism influences the biological effects of drugs and targets. The Seahorse XFe96 Analyzer is a label-free analysis platform that enables simultaneous measurement of mitochondrial function and glycolysis, enabling assessment of metabolic phenotype in live cells. This workshop will illustrate the use of a Bravo Automated Liquid Handling Platform for sample preparation prior to Seahorse XF Analysis.

Send Email for Lauren Dostillio

Kenda Evans

Automation Product SpecialistAgilent Technologies

Dr. Evans received her Ph.D. in Pharmacology from The University of Texas Health Science Center at San Antonio focusing on Serotonin 1A receptor pharmacology. She did a post-doc at the University of Houston, College of Pharmacy and Pharmaceutical Sciences concentrating on cardiovascular and respiratory pharmacology. Kenda joined Encysive Pharmaceuticals in the high throughput screening lab where she worked through many screening campaigns and had specific project management responsibilities. After 5 years with Encysive Pharmaceuticals, she joined PerkinElmer as a field application scientist with the high throughput screening reagents and plate readers group. In 2011 Kenda joined Agilent Technologies as a product specialist in the automation workflow group where she continues to work to build out new applications using the Bravo liquid handler for automated sample preparation.

Send Email for Kenda Evans

Sarah E. Burroughs

Product Manager, Seahorse XF InstrumentsAgilent Technologies

Dr. Burroughs received her Ph.D. in Chemistry from Penn State University, focusing on protein biochemistry. She did a post-doc at the University of Pittsburgh School of Medicine, then joined startup Cellomics Inc. in 1998 at the beginning of the era of high content screening. At Cellomics, Sarah worked in R&D and product development as well as product management. After acquisitions by Fisher Scientific then Thermo, Sarah worked as a field applications scientist for HCS products. After 11 years with Cellomics, Sarah joined PerkinElmer as an applications scientist with the automated liquid handling group. In 2013 Sarah became a product manager at Seahorse Bioscience, managing products and projects involving both assays and instruments. Seahorse Bioscience was acquired in 2015 by Agilent Technologies, where Sarah continues as a product marketing manager for Seahorse XF instruments.